Ironwood Q3 GAAP net income $50M; LINZESS Rx demand up 10% YoY, surpasses 1M quarterly scripts

IRONWOOD PHARMACEUTICALS INC

2022-Q3 EPS reported $0.69 revenue$303,397,000

GAAP net income of $50M ($0.28 diluted EPS); adjusted EBITDA $69M; total revenue $108.6M vs. $103.7M YoY.
LINZESS prescription demand grew 10% YoY in Q3; exceeded 1M total prescriptions in a quarter for first time.
Plan to submit sNDA to FDA for functional constipation in pediatric patients (ages 6-17) by end of 2022.
Reaffirms FY2022 guidance: total revenue $420-$430M, adjusted EBITDA >$250M, LINZESS net sales low single digit % growth.
Ended Q3 with $574M cash; no debt on balance sheet; strong liquidity position.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IRONWOOD PHARMACEUTICALS INC reported the quarter ended September 30, 2022 results: revenue $108,637, net income $50,317, EPS $0.33. Guidance reaffirmed.

Period: the quarter ended September 30, 2022
Revenue: $108,637
Net income: $50,317
EPS: $0.33
Guidance: reaffirmed
Result: reported results

Exact text from the filing

allocation continue to position our company for growth.” Third Quarter 2022 Financial Highlights 1 (in thousands, except for per share amounts) 3Q 2022 3Q 2021 Total revenues $ 108,637 $ 103,747 Total operating expenses 40,164 38,576 GAAP net income 50,317 55,845 GAAP net income per share – basic 0.33 0.34 GAAP net income per share – diluted 0.28 0.34 Adjusted

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

IRONWOOD PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-22-114196

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.